Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Y3 RNA, also known as RNA, Ro-associated Y3 (RNY3), is a member of the Y RNA family of noncoding RNAs transcribed by RNA polymerase III[1][2]. Its length is typically around 100 nucleotides. Y3 RNA forms a highly conserved stem-loop structure and binds specifically to the ring-shaped Ro60 protein, forming a critical part of the Ro ribonucleoprotein complex[1]. This association stabilizes Y3 RNA in the cytoplasm, facilitates Ro60 nuclear export, and helps direct Ro60 to specific subcellular locations, particularly during apoptosis or cellular stress[1][2]. Y3 RNA also tethers Ro60 to specific effector proteins, giving rise to specialized ribonucleoprotein complexes with distinct cellular functions[3]. In context of autoimmunity, Y3 RNA as part of Ro60 RNP is a major autoantigen and is involved in immune cell activation, particularly through mechanisms involving toll-like receptors (TLRs) and Fc gamma receptors in the presence of anti-Ro60 antibodies[2]. There are no known drugs directly targeting Y3 RNA. Its clinical relevance is as a component of autoantigenic RNPs in rheumatic diseases rather than as a classical therapeutic target (e.g., receptor, enzyme, or transporter)[1][2]. Y3 RNA (RNY3) is a small noncoding RNA that binds Ro60 and is important for assembling ribonucleoprotein complexes central to RNA metabolism and immune system-related pathogenesis, especially in systemic autoimmune diseases. It is not a classical drug target or receptor, and there are no direct interacting drugs or established biomarker roles. Its primary biomedical significance lies in its role in forming autoantigenic complexes in autoimmune disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, Ro-associated Y3 (RNY3).